Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial

Danyal Ibrahim, Latha Dulipsingh, Lisa Zapatka, Reginald Eadie, Rebecca Crowell, Kendra Williams, Dorothy B Wakefield, Lisa Cook, Jennifer Puff, Syed A Hussain, Danyal Ibrahim, Latha Dulipsingh, Lisa Zapatka, Reginald Eadie, Rebecca Crowell, Kendra Williams, Dorothy B Wakefield, Lisa Cook, Jennifer Puff, Syed A Hussain

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19.

Methods: Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge.

Results: Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed.

Conclusions: Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.

Trial registration: ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.

Keywords: Adult respiratory distress syndrome; COVID-19; COVID-19 serotherapy; Hospital mortality; Length of stay; Phase II clinical trial; Plasma; Prospective studies; Severe acute respiratory syndrome coronavirus 2; Ventilation.

Figures

Fig. 1
Fig. 1
Flowchart of patients and outcomes. CP convalescent plasma, CMO comfort care only

References

    1. Johns Hopkins University & Medicine. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). . Accessed 6 Sept 2020.
    1. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2020. . Accessed 3 Aug 2020.
    1. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Med Virol. 2020. 10.1002/jmv.26326.
    1. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med. 2020;9(4):967. doi: 10.3390/jcm9040967.
    1. Gautier JF, Ravussin Y. A new symptom of COVID-19: loss of taste and smell. Obesity (Silver Spring) 2020;28(5):848. doi: 10.1002/oby.22809.
    1. Lu L, Zhang H, Zhan M, et al. Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm? Front Cell Dev Biol. 2020;8:677.
    1. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi: 10.1172/JCI137244.
    1. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133(11):1261–7.
    1. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020;133(9):1032–1038. doi: 10.1097/CM9.0000000000000775.
    1. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia. 2020;75(10):1340–9.
    1. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care. 2020;24(1):285. doi: 10.1186/s13054-020-03006-1.
    1. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1–e6.
    1. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, coronavirus disease 2019, and QT prolongation. JAMA Cardiol. 2020.. 10.1001/jamacardio.2020.1782.
    1. Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020. 10.1001/jamainternmed.2020.3596.
    1. US Department of Health and Human Services Food and Drug Administration (FDA). Investigational COVID-19 convalescent plasma: emergency INDs. March 2020. . Accessed 10 Apr 2020.
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi: 10.1093/infdis/jiu396.
    1. Sun M, Xu Y, He H, et al. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy. Int J Infect Dis. 2020;98:334–46.
    1. Zhang L, Pang R, Xue X, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY) 2020;12(8):6536–6542. doi: 10.18632/aging.103102.
    1. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–6.
    1. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi: 10.1001/jama.2020.4783.
    1. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–70.
    1. Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–7.
    1. Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888–97.
    1. Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the midwest. Res Sq. 2020. 10.21203/-39447/v1.
    1. Salazar E, Perez KK, Ashraf M, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol. 2020;190(8):1680–90.
    1. US Department of Health and Human Services Food and Drug Administration (FDA). COVID-19: developing drugs and biological products for treatment or prevention guidance for industry, May 2020. . Accessed 26 July 2020.
    1. Salazar E, Christensen PA, Graviss EA, et al. Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020:S0002-9440(20)30370-9.
    1. Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020:261784.
    1. Joyner MJ, Senefeld JW , Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 10.1101/2020.08.12.20169359.
    1. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020:102554.
    1. Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020:3539.
    1. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;S2213–2600(20):30316–30317.
    1. Intensive Care National Audit Research Center (ICNARC). ICNARC report on COVID-19 in critical care, July 2020. . Accessed 6 Sep 2020.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren